Clinical trials: Buprenorphine
Opiate Dependence, HIV Infections
Reducing Sex-Related HIV Risk Behaviors in Patients Receiving Treatment for Opioid Dependence
The major goal is to determine in patients entering buprenorphine treatment, the prevalence of specific sex-related HIV risk behaviors, their physician's screening of these behaviors and to evaluate the impact of risk reduction…
- Trial name
- Project RED (NCT00548275)
- Testing
- Enhanced Sexual Risk Management, Standard Sexual Risk Management
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Yale University
Opioid-Related Disorders, Substance-Related Disorders
Trial of Buprenorphine/Naloxone for Opiate Dependence - 2
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate dependence treatment.
- Trial name
- NCT00000353
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid-Related Disorders
Buprenorphine Detoxification - BBDVI - 19
The purpose of this study is to examine the long-term efficacy of alternate-day dosing schedules in promoting treatment compliance in the absence of confounding behavioral contingencies.
- Trial name
- NCT00000237
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder
This is an open-label, randomized, parallel-group multicenter study designed to evaluate the efficacy of the digital therapeutic OXD01 (MODIA) combined with sublingual buprenorphine/naloxone standard of care (SL BUP/NAL SOC)…
- Trial name
- NCT04948307
- Testing
- OXD01 digital therapy, Standard of Care
- Where
- 21 sites in United States
- Volunteers
- 437 people
- Sponsor
- Orexo AB
Opioid Use Disorder
STAMPS: South Carolina Buprenorphine Treatment Initiation, Adherence, and Retention Utilizing Mobile Health Units and Peer Support Specialists
The study is a 1-arm prospective interventional cohort quasi-experimental with retrospective control group. Enrolled participants will be compared to previously established mobile health patients, who did not work with a peer…
- Trial name
- NCT06384781
- Testing
- Peer Support Checklist
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Prisma Health-Upstate
Opioid Use Disorder, Criminal Justice
Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews
This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a…
- Conditions
- Opioid Use Disorder, Criminal Justice, Treatment Adherence and Compliance
- Trial name
- NCT06354465
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Lifespan
Opioid-related Disorders
Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access
Despite the undisputed effectiveness of agonist maintenance for treating opioid dependence, current capacity is inadequate to meet need in the U.S. and internationally.
- Trial name
- IBT (NCT02360007)
- Testing
- Interim Buprenorphine Treatment (IBT)
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Vermont Medical Center
Suicidal Ideation, Major Depressive Disorder
Anti-suicidal Effects of Buprenorphine In Depressed Individuals
This study aims to examine the effect of low-dose buprenorphine as an add-on to treatment-as-usual for suicidal ideation in individuals with major depression, and investigate the functional brain activity related to its potential…
- Trial name
- NCT05427981
- Testing
- Belbuca Buccal Product
- Where
- United States
- Sponsor
- New York State Psychiatric Institute
Opioid-use Disorder, Opioid Use, Unspecified
Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution…
- Conditions
- Opioid-use Disorder, Opioid Use, Unspecified, Buprenorphine Dependence
- Trial name
- Mother/BabyOUD (NCT03923374)
- Testing
- Subutex / Buprenorphine, Fetal & Neonatal MRI, DNA/Genetic/Pharmacokenetic Blood Draws
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Senthil Sadhasivam
Opiate Dependence
Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence
The purpose of this study is to evaluate a very low dose naltrexone-buprenorphine treatment to transfer opioid dependent individuals to extended release naltrexone injection (Vivitrol).
- Trial name
- BUP/NXT-VIVI (NCT01690546)
- Testing
- very low dose naltrexone, extended release naltrexone, buprenorphine/naloxone
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Paolo Mannelli
Methadone or Buprenorphine Detoxoxification
Galantamine and CBT4CBT Pilot to Prevent Relapse.
The investigators are proposing a randomized pilot feasibility study to evaluate the effects of galantamine versus placebo on preventing relapse to opioid use following tapering from methadone or buprenorphine maintenance…
- Trial name
- NCT03547622
- Testing
- MAT taper with galantamine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Yale University
Healthy
Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone
Phase 1 study to determine the pharmacokinetic profile of NanoBUP Capsules to Suboxone.
- Trial name
- NCT01260675
- Testing
- Buprenorphine HCl/Naloxone HCl
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- NanoSHIFT LLC
Opioid Use
Incentivizing Buprenorphine-Naloxone Initiation in Emergency Departments
This study seeks to test standard and behavioral economic-enhanced training strategies to bolster first-time Emergency Department-initiated buprenorphine-naloxone administration among Emergency Department providers.
- Trial name
- NCT03821103
- Testing
- Training, Behavioral economic enhanced arm
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Pennsylvania
Opioid-Related Disorders
Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence
Buprenorphine, a treatment for opioid dependence, can be mixed with naloxone, to limit abuse potential. The purpose of this study is to examine the effectiveness of buprenorphine/naloxone that is given at less than daily…
- Trial name
- NCT00134888
- Testing
- Buprenorphine/naloxone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute on Drug Abuse (NIDA)
Patients Undergoing Ankle Surgery
Duration of Analgesia After Popliteal Fossa Nerve Blockade: Effects of Dexamethasone and Buprenorphine
Patients scheduled to go home after ankle surgery at HSS typically receive a sciatic nerve block in the popliteal fossa and oral analgesic tablets (such as Percocet).
- Trial name
- NCT01277159
- Testing
- A. Control Nerve Block. IV Dexamethasone (4 mg)., B. Nerve Block with Dexamethasone (4 mg). IV saline., C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Hospital for Special Surgery, New York
Hepatitis C, Opioid-Related Disorders
Drug-Drug Interaction Study Between Telaprevir and Buprenorphine
The purpose of this study is to investigate the drug-drug interaction potential between telaprevir and buprenorphine/naloxone. An understanding of the interaction potential will help to determine whether buprenorphine dose…
- Trial name
- NCT01275599
- Testing
- telaprevir, buprenorphine/naloxone
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Substance Use Disorders, Substance Abuse
Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone
This is an open-label, single center study of The Bridge in patients with sustained remission of opiate dependence on established, low-dose MAT with buprenorphine. A fixed number of patients will be admitted to the study.
- Conditions
- Substance Use Disorders, Substance Abuse, Substance Use, Substance Dependence
- Trial name
- NCT03762798
- Testing
- The Bridge
- Where
- United States
- Sponsor
- The Cleveland Clinic
Heroin Dependence
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
The study is designed to compare the abuse liabilities of intranasal buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine.
- Trial name
- NCT01760473
- Testing
- Intranasal challenge drug
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Moderate to Severe Opioid-use Disorder
Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users
The primary objective of the induction phase of the study is to compare treatment retention of participants following rapid induction or standard of care (SoC) induction onto extended-release buprenorphine.
- Trial name
- NCT04995029
- Testing
- Transmucosal Buprenorphine, Extended-release Buprenorphine
- Where
- 29 sites in United States, Canada
- Volunteers
- 785 people
- Sponsor
- Indivior Inc.
Opioid Dependence, on Agonist Therapy
Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence
The purpose of this study was to assess safety, efficacy, and treatment retention following extended treatment with OX219, a higher-bioavailability buprenorphine/naloxone (BNX) sublingual tablet formulation in opioid-dependent…
- Trial name
- NCT01903005
- Testing
- Higher bioavailability BNX sublingual tablets
- Where
- 28 sites in United States
- Volunteers
- 668 people
- Sponsor
- Orexo AB